intellectual property

The waiver's timing and scope, plus the transfer of technological know-how and development of manufacturing infrastructure, will all be fiercely debated.
A new letter to President Biden calling for a temporary patent waiver doesn't have the signatures of Congress's biggest recipients of pharmaceutical industry money.